Abstracts tagged "Clinical research"

Abstract Number: 429 • 2013 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: 2-Year Data From the Repeat (Repeated Courses in Routine Clinical Practice) Study
Catalin Codreanu¹, Ioan Ancuta² and Ruxandra Ionescu³, ¹Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ²“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania
Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…
Abstract Number: L17 • 2013 ACR/ARHP Annual Meeting
Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults with Autoimmune Disease
Lawrence McAdam¹, Michael Eberhardson², William Grainger³, Kim Papp⁴, Stephen Hall⁵, Tina Sterling⁶, Jon Stek⁶, Lei Pang⁶, Yanli Zhao⁶, Ivan Chan⁶, Richard Haupt⁶, Janie Parrino⁶ and Jeffrey Silber⁶, ¹Advanced Rheumatology, Infusion and Clinical Research Center, Thousand Oaks, CA, ²Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Neurological Physicians of Arizona, Gilbert, AZ, ⁴K. Papp Clinical Research,, Waterloo, ON, Canada, ⁵Emeritus Research, Malvern, Australia, ⁶Merck & Co., Inc., Whitehouse Station, NJ
Background/Purpose: Patients with autoimmune diseases are often immunocompromised, resulting in higher incidence of HZ than in immunocompetent individuals with significant morbidity and occasional mortality from…
Abstract Number: 138 • 2013 ACR/ARHP Annual Meeting
Long Term Outcomes In Fibromyalgia
Lesley M. Arnold¹ and Thomas Blom², ¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, ²Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: There are few studies on the long-term prognosis of fibromyalgia. This study assessed the natural history of fibromyalgia in patients receiving usual medical care…
Abstract Number: 2544 • 2013 ACR/ARHP Annual Meeting
Serum Mediated Phagocytosis Of Necrotic Material By Polymorphonuclear Leukocytes May Be Used As a Tool To Predict Clinical Manifestations In Systemic Lupus Erythematosus
Michele Compagno¹, Birgitta Gullstrand², Andreas Jönsen³, Lennart Truedsson², Gunnar Sturfelt⁴ and Anders A. Bengtsson³, ¹Department of clinical sciences - Rheumatology, Lund University, Lund, Sweden, ²Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ³Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ⁴Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: Polymorphonuclear (PMNs) leukocytes with engulfed necrotic cell material (NCM), as formerly used in the LE-cell test, are frequently seen in SLE and associated to…
Abstract Number: 2286 • 2013 ACR/ARHP Annual Meeting
Reliability and Smallest Detectable Difference Of The Patient Global Assessment, Pain and Fatigue In Rheumatoid Arthritis Patients
Paul Studenic¹, Josef S. Smolen^2,3 and Daniel Aletaha⁴, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²PsAID taskforce, EULAR, Zurich, Switzerland, ³2nd Department of Medicine, Krankenhaus Lainz, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Patient reported outcomes (PRO) represent an important part of outcomes assessment in rheumatoid arthritis (RA) patients. The Patient Global Assessment (PGA) is an essential…
Abstract Number: 2050 • 2013 ACR/ARHP Annual Meeting
Arthralgia Occurring Under Aromatase Inhibitor Treatment For Breast Cancer. A Prospective Study
Daniel Wendling¹, Helene Letho-Gyselinck¹, Xavier Guillot², Clément Prati³ and Xavier Pivot⁴, ¹Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ²Department of Rheumatology, CHRU Besançon, Besançon, France, ³Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁴Oncology, CHRU Besançon, Besançon, France
Background/Purpose: Treatment with third generation aromatase inhibitors (AI) is associated with occurrence of arthralgia, with an incidence ranging from 25 to 45 %. In these…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].